The prince and the pauper. A tale of anticancer targeted agents

Molecular Cancer

Volumn 7, Issue , 2008, Pages

  Dueñas González, Alfonso ^a,c   García López, Patricia ^a   Herrera, Luis Alonso ^a   Medina Franco, Jose Luis ^b   González Fierro, Aurora ^a   Candelaria, Myrna ^a  

^a INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^b TORREY PINES INSTITUTE FOR MOLECULAR STUDIES   (United States)

^c U de Invest Biomedica en Cancer   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTINEOPLASTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CHLOROQUINE; DEXAMETHASONE; DIGITALIS; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; FLUOROURACIL; GLITAZONE DERIVATIVE; GLYCERYL TRINITRATE; HYDRALAZINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYDROXYUREA; IFOSFAMIDE; LISINOPRIL; MESNA; NIFEDIPINE; PLACEBO; PROCAINAMIDE; PROCAINE; TETRAHYDROLIPSTATIN; UNINDEXED DRUG; VALPROIC ACID; VERAPAMIL; VINCRISTINE; VINDESINE;

ABDOMINAL PAIN; ABNORMAL FECES; ABSENCE OF SIDE EFFECTS; ACUTE KIDNEY FAILURE; ANEMIA; ANGINA PECTORIS; ANGIONEUROTIC EDEMA; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ATRIOVENTRICULAR BLOCK; AUTOIMMUNE DISEASE; BLURRED VISION; BREAST CANCER; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER INCIDENCE; CANCER INHIBITION; CANCER MORTALITY; CANCER PREVENTION; CANCER RESISTANCE; CANCER SURVIVAL; CHOLELITHIASIS; CHOLESTATIC HEPATITIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; COUGHING; DIABETES MELLITUS; DIAPHORESIS; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COMPETITION; DRUG COST; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG INDUSTRY; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SAFETY; DRUG SELECTIVITY; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG TARGETING; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FLUSHING; GASTROINTESTINAL TOXICITY; HEART ARRHYTHMIA; HEART FAILURE; HEART PALPITATION; HUMAN; HYPERTENSION; HYPOTENSION; ISCHEMIC HEART DISEASE; LIVER FAILURE; LIVER INJURY; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUPUS LIKE SYNDROME; MALARIA; MAXIMUM PLASMA CONCENTRATION; MENINGIOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYOPATHY; NAUSEA; NAUSEA AND VOMITING; NEOPLASM; NONHUMAN; OBESITY; ORTHOSTATIC HYPOTENSION; OVARY CARCINOMA; PERIPHERAL EDEMA; RECOMMENDED DRUG DOSE; REPEATED DRUG DOSE; RETINOPATHY; REVIEW; RHABDOMYOLYSIS; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; SYNCOPE; TACHYCARDIA; TERATOGENICITY; TREMOR; UNSPECIFIED SIDE EFFECT; URINE INCONTINENCE; UTERINE CERVIX CARCINOMA; VOMITING; WEIGHT GAIN; ANIMAL; CLASSIFICATION; DRUG DEVELOPMENT; DRUG SCREENING; ECONOMICS; METHODOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; DRUG INDUSTRY; HUMANS; NEOPLASMS;

EID: 58249116704     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-7-82     Document Type: Review

References (418)

1. Mignogna MD Fedele S Lo Russo L The World Cancer Report and the burden of oral cancer Eur J Cancer Prev 2004, 13:139-142 10.1097/ 00008469-200404000-00008 15100581
2. Brenner H Gondos A Arndt V Recent major progress in long-term cancer patient survival disclosed by modeled period analysis J Clin Oncol 2007, 25:3274-3280 10.1200/JCO.2007.11.3431 17664474
3. Traxler P Tyrosine kinases as targets in cancer therapy - successes and failures Expert Opin Ther Targets 2003, 7:215-234 10.1517/ 14728222.7.2.215 12667099
4. Stern M Herrmann R Overview of monoclonal antibodies in cancer therapy: present and promise Crit Rev Oncol Hematol 2005, 54:11-29 10.1016/ j.critrevonc.2004.10.011 15780905
5. Danzon PM Towse A Differential pricing for pharmaceuticals: Reconciling access, R&D and patents Int J Health Care Finance Econ 2003, 3:183-205 10.1023/A:1025384819575 14625999
6. Serajuddin HK Serajuddin AT Value of pharmaceuticals: Ensuring the future of research and development J Am Pharm Assoc 2006, 46:511-516 10.1331/154434506778073682
7. Barton JH Emanuel EJ The patents-based pharmaceutical development process: Rationale, problems, and potential reforms JAMA 2005, 294:2075-2082 10.1001/jama.294.16.2075 16249422
8. Verkman AS Drug discovery in academia Am J Physiol Cell Physiol 2004, 286:465-474 10.1152/ajpcell.00397.2003
9. O'Connor KA Roth BL Finding new tricks for old drugs: An efficient route for public-sector drug discovery Nat Rev Drug Discov 2005, 4:1005-1014 10.1038/nrd1900 16341065
10. Ashburn TT Thor KB Drug repositioning: Identifying and developing new uses for existing drugs Nat Rev Drug Discov 2004, 3:673-683 10.1038/ nrd1468 15286734
11. Langtry HD Markham A Sildenafil: A review of its use in erectile dysfunction Drugs 1999, 57:967-989 10.2165/00003495-199957060-00015 10400408
12. Clapham DE Calcium signaling Cell 1995, 80:259-268 10.1016/ 0092-8674(95)90408-5 7834745
13. Bean BP Classes of calcium channels in vertebrate cells Ann Rev Physiol 1989, 51:367-384 10.1146/annurev.ph.51.030189.002055
14. Triggle DJ The classification of calcium antagonists J Cardiovasc Phamacol 1996, 27(suppl):S13
15. Triggle DJ Calcium channel antagonists: Mechanisms of action, vascular selectivities and clinical relevance Clev Clin J Med 1992, 59:617-627
16. Rasmussen II Barret PQ Calcium messenger system: An integrated view Physiol Rev 1984, 64:938-984 6330778
17. Durham AC Walton JM Calcium ions and the control of proliferation in normal and cancer cells Biosci Rep 1982, 2:1S-30 10.1007/BF01142195
18. Nishizuka Y The role of protein kinase C in cell surface signal transduction and tumor promotion Nature 1984, 308:693-698 10.1038/ 308693a0 6232463
19. Metcalfe JC Pozzan T Smith GA A calcium hypothesis for the control of cell growth Biochem Soc Symp 1980, 45:1-26 6783043
20. Taylor JM Simpson RU Inhibition of cancer cell growth by calcium channel antagonists in the athymic mouse Cancer Res 1992, 52:2413-2418 1533173
21. Timar J Chopra H Rong X Hatfield JS Fligiel SE Onoda JM Taylor JD Honn KV Calcium channel blocker treatment of tumor cells induces alterations in the cytoskeleton, mobility of the integrin alpha IIb beta 3 and tumor-cell-induced platelet aggregation J Cancer Res Clin Oncol 1992, 118:425-434 10.1007/BF01629425 1377695
22. Roger S Le Guennec JY Besson P Particular sensitivity to calcium channel blockers of the fast inward voltage-dependent sodium current involved in the invasive properties of a metastastic breast cancer cell line Br J Pharmacol 2004, 141:610-615 10.1038/sj.bjp.0705649 14744811 1574233
23. Yoshida J Ishibashi T Nishio M Antiproliferative effect of Ca2+ channel blockers on human epidermoid carcinoma A431 cells Eur J Pharmacol 2003, 472:23-31 10.1016/S0014-2999(03)01831-4 12860469
24. Lee YS Sayeed MM Wurster RD Inhibition of cell growth and intracellular Ca2+ mobilization in human brain tumor cells by Ca2+ channel antagonists Mol Chem Neuropathol 1994, 22:81-95 7522451
25. Yao X Kwan HY Activity of voltage-gated K+ channels is associated with cell proliferation and Ca2+ influx in carcinoma cells of colon cancer Life Sci 1999, 65:55-62 10.1016/S0024-3205(99)00218-0 10403493
26. Fraser SP Grimes JA Djamgoz MB Effects of voltage-gated ion channel modulators on rat prostatic cancer cell proliferation: Comparison of strongly and weakly metastatic cell lines Prostate 2000, 44:61-76 10.1002/1097-0045(20000615)44:1<61::AID-PROS9>3.0.CO;2-3 10861759
27. Pancrazio JJ Viglione MP Kleiman RJ Kim YI Verapamil-induced blockade of voltage-activated K+ current in small-cell lung cancer cells J Pharmacol Exp Ther 1991, 257:184-191 1850464
28. Bertrand V Bastié MJ Vaysse N Pradayrol L Inhibition of gastrin-induced proliferation of AR4-2J cells by calcium channel antagonists Int J Cancer 1994, 56:427-432 10.1002/ijc.2910560324 7508895
29. Tan B Piwnica-Worms D Ratner L Multidrug resistance transporters and modulation Curr Opin Oncol 2000, 12:450-458 10.1097/ 00001622-200009000-00011 10975553
30. Belpomme D Gauthier S Pujade-Lauraine E Facchini T Goudier MJ Krakowski I Netter-Pinon G Frenay M Gousset C Marié FN Benmiloud M Sturtz F Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma Ann Oncol 2000, 11:1471-1476 10.1023/A:1026556119020 11142488
31. Millward MJ Cantwell BM Munro NC Robinson A Corris PA Harris AL Oral verapamil with chemotherapy for advanced non-small-cell lung cancer: A randomised study Br J Cancer 1993, 67:1031-1035 8388231
32. Dalton WS Crowley JJ Salmon SS Grogan TM Laufman LR Weiss GR Bonnet JD A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study Cancer 1995, 75:815-820 10.1002/ 1097-0142(19950201)75:3<815::AID-CNCR2820750311>3.0.CO;2-R 7828131
33. Richardson PG Sonneveld P Schuster MW Irwin D Stadtmauer EA Facon T Harousseau JL Ben-Yehuda D Lonial S Goldschmidt H Reece D San-Miguel JF Bladé J Boccadoro M Cavenagh J Dalton WS Boral AL Esseltine DL Porter JB Schenkein D Anderson KC Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators Bortezomib or high-dose dexamethasone for relapsed multiple myeloma N Engl J Med 2005, 352:2487-2498 10.1056/NEJMoa043445 15958804
34. Jensen RL Wurster RD Calcium channel antagonists inhibit growth of subcutaneous xenograft meningiomas in nude mice Surg Neurol 2001, 55:275-583 10.1016/S0090-3019(01)00444-X 11516467
35. Jensen RL Petr M Wurster RD Calcium channel antagonist effect on in vitro meningioma signal transduction pathways after growth factor stimulation Neurosurgery 2000, 46:692-702 10.1097/ 00006123-200003000-00032 10719866
36. Jensen RL Leppla D Rokosz N Wurster RD Matrigel augments xenograft transplantation of meningioma cells into athymic mice Neurosurgery 1998, 42:130-135 10.1097/00006123-199801000-00027 9442514
37. Jensen RL Lee YS Guijrati M Origitano TC Wurster RD Reichman OH Inhibition of in vitro meningioma proliferation after growth factor stimulation by calcium channel antagonists: Part II - Additional growth factors, growth factor receptor immunohistochemistry, and intracellular calcium measurements Neurosurgery 1995, 37:937-946 10.1097/ 00006123-199511000-00013 8559343
38. Jensen RL Origitano TC Lee YS Weber M Wurster RD In vitro growth inhibition of growth factor-stimulated meningioma cells by calcium channel antagonists Neurosurgery 1995, 36:365-373 10.1097/ 00006123-199502000-00017 7731518
39. Ragel BT Gillespie DL Kushnir V Polevaya N Kelly D Jensen RL Calcium channel antagonists augment hydroxyurea- and ru486-induced inhibition of meningioma growth in vivo and in vitro Neurosurgery 2006, 59:1109-1120 10.1227/01.NEU.0000232864.73007.38 17143245
40. Ragel BT Couldwell WT Wurster RD Jensen RL Chronic suppressive therapy with calcium channel antagonists for refractory meningiomas Neurosurg Focus 2007, 23:E10 10.3171/FOC-07/10/E10 17961034
41. Leier CV General overview and update of positive inotropic therapy Am J Med 1986, 81:40-45 10.1016/0002-9343(86)90944-7 2946223
42. Horwitz LD Congestive heart failure. An overview of drug therapy Postgrad Med 1984, 76:187-190 6146965
43. Mastropietro C Digitalis: An overview AANA J 1983, 51:261-266 6310923
44. Iisalo E Clinical pharmacokinetics of digoxin Clin Pharmacokinet 1977, 2:1-16 10.2165/00003088-197702010-00001 322907
45. Mooradian AD Digitalis. An update of clinical pharmacokinetics, therapeutic monitoring techniques and treatment recommendations Clin Pharmacokinet 1988, 15:165-179 10.2165/00003088-198815030-00002 3052985
46. Lee TH Smith TW Serum digoxin concentration and diagnosis of digitalis toxicity. Current concepts Clin Pharmacokinet 1983, 8:279-285 10.2165/ 00003088-198308040-00001 6617041
47. Ujhelyi MR Robert S Pharmacokinetic aspects of digoxin-specific Fab therapy in the management of digitalis toxicity Clin Pharmacokinet 1995, 28:483-493 10.2165/00003088-199528060-00006 7656506
48. Ahmed A Rich MW Love TE Lloyd-Jones DM Aban IB Colucci WS Adams KF Gheorghiade M Digoxin and reduction in mortality and hospitalization in heart failure: A comprehensive post hoc analysis of the DIG trial Eur Heart J 2006, 27:178-186 10.1093/eurheartj/ehi687 16339157
49. The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group N Engl J Med 1997, 336:525-533 10.1056/NEJM199702203360801 9036306
50. Friedman GD Digitalis and breast cancer Lancet 1984, 2:875 10.1016/ S0140-6736(84)90915-2 6148608
51. López-Lázaro M Pastor N Azrak SS Ayuso MJ Austin CA Cortés F Digitoxin inhibits the growth of cancer cell lines at concentrations commonly found in cardiac patients J Nat Prod 2005, 68:1642-1645 10.1021/np050226l 16309315
52. Gupta RS Chopra A Stetsko DK Cellular basis for the species differences in sensitivity to cardiac glycosides (digitalis) J Cell Physiol 1986, 127:197-206 10.1002/jcp.1041270202 3009493
53. Schoner W Scheiner-Bobis G Endogenous and exogenous cardiac glycosides: their roles in hypertension, salt metabolism, and cell growth Am J Physiol Cell Physiol 2007, 293:509-536 10.1152/ajpcell.00098.2007
54. Newman RA Yang P Pawlus AD Cardiac glycosides as novel cancer therapeutic agents Mol Interv 2008, 8:36-49 10.1124/mi.8.1.8 18332483
55. Kometiani P Liu L Askari A Digitalis-induced signaling by Na+/K+-ATPase in human breast cancer cells Mol Pharmacol 2005, 67:929-936 10.1124/ mol.104.007302 15602003
56. Mijatovic T Van Quaquebeke E Delest B Cardiotonic steroids on the road to anti-cancer therapy Biochim Biophys Acta 2007, 1776:32-57 17706876
57. Chen JQ Contreras RG Wang R Sodium/potassium ATPase (Na+, K+-ATPase) and ouabain/related cardiac glycosides: A new paradigm for development of anti-breast cancer drugs? Breast Cancer Res Treat 2006, 96:1-15 10.1007/ s10549-005-9053-3 16322895
58. Nesher M Shpolansky U Rosen H The digitalislike steroid hormones: New mechanisms of action and biological significance Life Sci 2007, 80:2093-2107 10.1016/j.lfs.2007.03.013 17499813
59. Raghavendra PB Sreenivasan Y Ramesh GT Manna SK Cardiac glycoside induces cell death via FasL by activating calcineurin and NF-AT, but apoptosis initially proceeds through activation of caspases Apoptosis 2007, 12:307-318 10.1007/s10495-006-0626-3 17203245
60. Sreenivasan Y Raghavendra PB Manna SK Oleandrin-mediated expression of Fas potentiates apoptosis in tumor cells J Clin Immunol 2006, 26:308-322 10.1007/s10875-006-9028-0 16779680
61. Frese SM Andres AC Miescher D Cardiac glycosides initiate Apo2L/ TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5 Cancer Res 2006, 66:5867-5874. 10.1158/0008-5472.CAN-05-3544 16740726
62. Newman RA Kondo Y Yokoyama T Dixon S Cartwright C Chan D Johansen M Yang P Autophagic cell death of human pancreatic tumor cells mediated by oleandrin, a lipid-soluble cardiac glycoside Integr Cancer Ther 2007, 6:354-364. 10.1177/1534735407309623 18048883
63. López Lázaro M Digitoxin as an anticancer agent with selectivity for cancer cells: Possible mechanisms involved Expert Opin Ther Targets 2007, 11:1043-1053. 10.1517/14728222.11.8.1043 17665977
64. Johansson S Lindholm P Gullbo J Larsson R Bohlin L Claeson P Cytotoxicity of digitoxin and related cardiac glycosides in human tumor cells Anticancer Drugs 2001, 12:475-483. 10.1097/ 00001813-200106000-00009 11395576
65. Verheye Dua F Böhm L Na+, K+-ATPase inhibitor, ouabain accentuates irradiation damage in human tumour cell lines Radiat Oncol Investig 1998, 6:109-119. 10.1002/ (SICI)1520-6823(1998)6:3<109::AID-ROI1>3.0.CO;2-1 9652909
66. Verheye Dua FA Böhm L Influence of apoptosis on the enhancement of radiotoxicity by ouabain Strahlenther Onkol 2000, 176:186-191. 10.1007/ s000660050055 10812392
67. Lawrence TS Ouabain sensitizes tumor cells but not normal cells to radiation Int J Radiat Oncol Biol Phys 1988, 15:953-958. 3182336
68. Sakai H Suzuki T Maeda M Takahashi Y Horikawa N Minamimura T Tsukada K Takeguchi N Up-regulation of Na+, K+-ATPase in alpha-3-isoform and down-regulation of the alpha-1-isoform in human colorectal cancer FEBS Lett 2004, 563:151-154. 10.1016/S0014-5793(04)00292-3 15063740
69. Lefranc F Mijatovic T Kondo Y Sauvage S Roland I Debeir O Krstic D Vasic V Gailly P Kondo S Blanco G Kiss R Targeting the alpha 1 subunit of the sodium pump to combat glioblastoma cells Neurosurgery 2008, 62:211-221. 18300910
70. Lefranc F Kiss R The sodium pump alpha1 subunit as a potential target to combat apoptosis-resistant glioblastomas Neoplasia 2008, 10:198-206. 2259449 18323016
71. Mijatovic T Roland I Van Quaquebeke E Nilsson B Mathieu A Van Vynckt F Darro F Blanco G Facchini V Kiss R The alpha1 subunit of the sodium pump could represent a novel target to combat non-small cell lung cancers J Pathol 2007, 212:170-179. 10.1002/path.2172 17471453
72. Atlas SA The renin-angiotensin aldosterone system: Pathophysiological role and pharmacologic inhibition J Manag Care Pharm 2007, 13:9-20. 17970613
73. Israili ZH Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension J Hum Hypertens 2000, 14:73-86. 10.1038/ sj.jhh.1000991
74. Califf RM Cohn JN Cardiac protection: Evolving role of angiotensin receptor blockers Am Heart J 2000, 139:15-22. 10.1067/mhj.2000.102903 10618557
75. Suzuki Y Ruiz-Ortega M Egido J Angiotensin II: A double-edged sword in inflammation. J Nephrol 2000(Suppl 3):S101-S110.
76. Unger T Pharmacological properties of angiotensin II antagonists: examining all the therapeutic implications J Renin Angiotensin Aldosterone Syst 2001, 2:4-7. 10.3317/jraas.2001.030 11881054
77. McAreavey D Robertson JI Angiotensin converting enzyme inhibitors and moderate hypertension Drugs 1990, 40:326-345. 10.2165/ 00003495-199040030-00002 2226219
78. Nielsen EW Hypotensive shock and angio-oedema from angiotensin II receptor blocker: A class effect in spite of tripled tryptase values J Intern Med 2005, 258:385-387. 10.1111/j.1365-2796.2005.01547.x 16164579
79. Israel G Shani R Azaz-Livshits T Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure: An observational study of treatment rates and clinical outcome Isr Med Assoc J 2008, 10:214-218. 18494235
80. Vrijens B Vincze G Kristanto P Adherence to prescribed antihypertensive drug treatments: Longitudinal study of electronically compiled dosing histories BMJ 2008, 336:1114. 10.1136/bmj.39553.670231.25 18480115 2386633
81. Morimoto T Gandhi TK Fiskio JM An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors J Eval Clin Pract 2004, 10:499-509. 10.1111/j.1365-2753.2003.00484.x 15482412
82. Schaefer C Angiotensin II-receptor-antagonists: Further evidence of fetotoxicity but not teratogenicity Birth Defects Res A Clin Mol Teratol 2003, 67:591-594. 10.1002/bdra.10081 14632309
83. Bowen ME Ray WA Arbogast PG Ding H Cooper WO Increasing exposure to angiotensin-converting enzyme inhibitors in pregnancy Am J Obstet Gynecol 2008, 198:291. 10.1016/j.ajog.2007.09.009 18191803
84. Deshayes F Nahmias C Angiotensin receptors: A new role in cancer? Trends Endocrinol Metab 2005, 16:293-299. 10.1016/j.tem.2005.07.009 16061390
85. Lever AF Hole DJ Gillis CR McCallum IR McInnes GT MacKinnon PL Meredith PA Murray LS Reid JL Robertson JW Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 1998, 352:179-184. 10.1016/S0140-6736(98)03228-0 9683206
86. Koh WP Yuan JM Sun CL Berg van den D Seow A Lee HP Yu MC Angiotensin I-converting enzyme (ACE) gene polymorphism and breast cancer risk among Chinese women in Singapore Cancer Res 2003, 63:573-578. 12566298
87. Medeiros R Vasconcelos A Costa S Pinto D Lobo F Morais A Oliveira J Lopes C Linkage of angiotensin I-converting enzyme gene insertion/ deletion polymorphism to the progression of human prostate cancer J Pathol 2004, 202:330-335. 10.1002/path.1529 14991898
88. Röcken C Lendeckel U Dierkes J Westphal S Carl-McGrath S Peters B Krüger S Malfertheiner P Roessner A Ebert MP The number of lymph node metastases in gastric cancer correlates with the angiotensin I-converting enzyme gene insertion/deletion polymorphism Clin Cancer Res 2005, 11:2526-2530. 10.1158/1078-0432.CCR-04-1922 15814629
89. Yoshiji H Kuriyama S Fukui H Angiotensin-I-converting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor Tumour Biol 2002, 23:348-356. 10.1159/ 000069792 12677092
90. Yasumatsu R Nakashima T Masuda M Ito A Kuratomi Y Nakagawa T Komune S Effects of the angiotensin-I converting enzyme inhibitor perindopril on tumor growth and angiogenesis in head and neck squamous cell carcinoma cells J Cancer Res Clin Oncol 2004, 130:567-573. 10.1007/ s00432-004-0582-7 15449186
91. Volpert OV Ward WF Lingen MW Chesler L Solt DB Johnson MD Molteni A Polverini PJ Bouck NP Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats J Clin Invest 1996, 98:671-679. 10.1172/JCI118838 8698858 507476
92. Hii SI Nicol DL Gotley DC Thompson LC Green MK Jonsson JR Captopril inhibits tumour growth in a xenograftmodel of human renal cell carcinoma Br J Cancer 1998, 77:880-883. 9528828
93. Yoshiji H Kuriyama S Fukui H Perindopril: Possible use in cancer therapy Anticancer Drugs 2002, 13:221-228. 10.1097/00001813-200203000-00003 11984065
94. Miyajima A Kosaka T Asano T Asano T Seta K Kawai T Hayakawa M Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis Cancer Res 2002, 62:4176-4179. 12154013
95. Arrieta O Guevara P Escobar E García-Navarrete R Pineda B Sotelo J Blockage of angiotensin II type 1 receptor decreases the synthesis of growth factors and induces apoptosis in C6 cultured cells and C6 rat glioma Br J Cance 2005, 92:1247-1252. 10.1038/sj.bjc.6602483
96. Kosugi M Miyajima A Kikuchi E Kosaka T Horiguchi Y Murai M Effect of angiotensin II type 1 receptor antagonist on tumor growth and angiogenesis in a xenograft model of human bladder cancer Hum Cell 2007, 20:1-9. 10.1111/j.1749-0774.2007.00025.x 17506771
97. Suganuma T Ino K Shibata K Kajiyama H Nagasaka T Mizutani S Kikkawa F Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination Clin Cancer Res 2005, 11:2686-2694. 10.1158/ 1078-0432.CCR-04-1946 15814650
98. Kosaka T Miyajima A Takayama E Kikuchi E Nakashima J Ohigashi T Asano T Sakamoto M Okita H Murai M Hayakawa M Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in prostate cancer Prostate 2007, 67:41. 10.1002/pros.20486 17044086
99. Puddefoot JR Udeozo UK Barker S Vinson GP The role of angiotensin II in the regulation of breast cancer cell adhesion and invasion Endocr Relat Cancer 2006, 13:895-903. 10.1677/erc.1.01136 16954438
100. Neo JH Malcontenti-Wilson C Muralidharan V Christophi C Effect of ACE inhibitors and angiotensin II receptor antagonists in a mouse model of colorectal cancer liver metastases J Gastroenterol Hepatol 2007, 22:577-584. 10.1111/j.1440-1746.2006.04797.x 17376054
101. Huang W Wu YL Zhong J Jiang FX Tian XL Yu LF Angiotensin II type 1 receptor antagonist suppress angiogenesis and growth of gastric cancer xenografts Dig Dis Sci 2008, 53:1206-1210. 10.1007/s10620-007-0009-9 17934850
102. Fujiyama S Matsubara H Nozawa Y Maruyama K Mori Y Tsutsumi Y Masaki H Uchiyama Y Koyama Y Nose A Iba O Tateishi E Ogata N Jyo N Higashiyama S Iwasaka T Angiotensin AT(1) and AT(2) receptors differentially regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated EGF receptor transactivation Circ Res 2001, 88:22-29. 11139469
103. Shah BH Yesilkaya A Olivares-Reyes JA Chen HD Hunyady L Catt KJ Differential pathways of angiotensin II-induced extracellularly regulated kinase 1/2 phosphorylation in specific cell types: Role of heparin-binding epidermal growth factor Mol Endocrinol 2004, 18:2035-2048. 10.1210/me.2003-0476 15143154
104. Smith NJ Chan HW Osborne JE Thomas WG Hannan RD Hijacking epidermal growth factor receptors by angiotensin II: New possibilities for understanding and treating cardiac hypertrophy Cell Mol Life Sci 2004, 61:2695-2703. 10.1007/s00018-004-4244-3 15549170
105. Itabashi H Maesawa C Oikawa H Kotani K Sakurai E Kato K Komatsu H Nitta H Kawamura H Wakabayashi G Masuda T Angiotensin II and epidermal growth factor receptor cross-talk mediated by a disintegrin and metalloprotease accelerates tumor cell proliferation of hepatocellular carcinoma cell lines Hepatol Res 2008, 38:601-613. 10.1111/j.1872-034X.2007.00304.x 18452483
106. Imai N Hashimoto T Kihara M Yoshida S Kawana I Yazawa T Kitamura H Umemura S Roles for host and tumor angiotensin II type 1 receptor in tumor growth and tumor-associated angiogenesis Lab Invest 2007, 87:189-198. 10.1038/labinvest.3700504 17318197
107. Fujita M Hayashi I Yamashina S Fukamizu A Itoman M Majima M Angiotensin type 1a receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth Carcinogenesis 2005, 26:271-279. 10.1093/carcin/bgh324 15637093
108. Ruiz-Ortega M Lorenzo O Suzuki Y Egido J Proinflammatory actions of angiotensins Curr Opin Nephrol Hypertens 2001, 10:321-329. 10.1097/ 00041552-200105000-00005 11342793
109. Suzuki Y Ruiz-Ortega M Egido J Angiotensin II: A double-edged sword in inflammation J Nephrol 2000, 13:101-110.
110. Erbe DV Gartrell K Zhang YL Suri V Kirincich SJ Will S Perreault M Wang S Tobin JF Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists Vascul Pharmacol 2006, 45:154-162. 10.1016/ j.vph.2006.05.002 16765099
111. Uemura H Hasumi H Kawahara T Sugiura S Miyoshi Y Nakaigawa N Teranishi J Noguchi K Ishiguro H Kubota YT Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer Int J Clin Oncol 2005, 10:405-410. 10.1007/s10147-005-0520-y 16369744
112. Beyar R Controlling ischemic cardiovascular disease: From basic mechanisms to clinical management Ann N Y Acad Sci 2008, 1123:232-2326. 10.1196/annals.1420.026 18375595
113. Cohn PF Treatment of chronic myocardial ischemia: Rationale and treatment options Cardiovasc Drugs Ther 1998, 12:217-223. 10.1023/ A:1007782210758 9800050
114. Abrams J Beneficial actions of nitrates in cardiovascular disease Am J Cardiol 1996, 77:31-37. 10.1016/S0002-9149(96)00186-5 8540453
115. Chen Z Zhang J Stamler JS Identification of the enzymatic mechanism of nitroglycerin bioactivation Proc Natl Acad Sci USA 2002, 99:8306-8311. 10.1073/pnas.122225199 12048254 123063
116. Butler AR Feelisch M Therapeutic uses of inorganic nitrite and nitrate: from the past to the future Circulation 2008, 117:2151-2159. 10.1161/ CIRCULATIONAHA.107.753814 18427145
117. Thadani U Ripley TL Side effects of using nitrates to treat heart failure and the acute coronary syndromes, unstable angina and acute myocardial infarction Expert Opin Drug Saf 2007, 6:385-396. 10.1517/ 14740338.6.4.385 17688382
118. Brahimi-Horn MC Chiche J Pouysségur J Hypoxia and cancer J Mol Med 2007, 85:1301-1307. 10.1007/s00109-007-0281-3 18026916
119. Matthews NE Adams MA Maxwell LR Nitric oxide-mediated regulation of chemosensitivity in cancer cells J Natl Cancer Inst 2001, 93:1879-1885. 10.1093/jnci/93.24.1879 11752013
120. Frederiksen LJ Siemens DR Heaton JP Maxwell LR Adams MA Graham CH Hypoxia induced resistance to doxorubicin in prostate cancer cells is inhibited by low concentrations of glyceryl trinitrate J Urol 2003, 170:1003-1007. 10.1097/01.ju.0000081126.71235.e0 12913759
121. Muir CP Adams MA Graham CH Nitric oxide attenuates resistance to doxorubicin in three-dimensional aggregates of human breast carcinoma cells Breast Cancer Res Treat 2006, 96:169-176. 10.1007/ s10549-005-9076-9 16331349
122. Postovit LM Adams MA Lash GE Heaton JP Graham CH Nitric oxide-mediated regulation of hypoxia-induced B16F10 melanoma metastasis Int J Cancer 2004, 108:47-53. 10.1002/ijc.11556 14618614
123. Sullivan R Graham CH Chemosensitization of cancer by nitric oxide Curr Pharm Des 2008, 14:1113-1123. 10.2174/138161208784246225 18473858
124. Mannick JB Schonhoff CM NO means no and yes: Regulation of cell signaling by protein nitrosylation Free Radic Res 2004, 38:1-7. 10.1080/ 10715760310001629065 15061648
125. Chung HT Pae HO Choi BM Nitric oxide as a bioregulator of apoptosis Biochem Biophys Res Commun 2001, 282:1075-1079. 10.1006/bbrc.2001.4670 11302723
126. Ahern P Klyachko VA Jackson MB cGMP and S-nitrosylation: Two routes for modulation of neuronal excitability by NO Trends Neurosci 2002, 25:510-517. 10.1016/S0166-2236(02)02254-3 12220879
127. Blaise GA Gauvin D Gangal M Authier S Nitric oxide, cell signaling and cell death Toxicology 2005, 208:177-192. 10.1016/j.tox.2004.11.032 15691583
128. Frederiksen LJ Sullivan R Maxwell LR Macdonald-Goodfellow SK Adams MA Bennett BM Siemens DR Graham CH Chemosensitization of cancer in vitro and in vivo by nitric oxide signaling Clin Cancer Res 2007, 13:2199-2206. 10.1158/1078-0432.CCR-06-1807 17404104
129. Nathan C Xie QW Regulation of biosynthesis of nitric oxide J Biol Chem 1994, 269:13725-13728. 7514592
130. Whorton AR Simonds DB Piantadosi CA Regulation of nitric oxide synthesis by oxygen in vascular endothelial cells Am J Physiol 1997, 272:1161-1166.
131. McCormick CC Li WP Calero M Oxygen tension limits nitric oxide synthesis by activated macrophages Biochem J 2000, 350:709-716. 10.1042/ 0264-6021:3500709 10970783 1221301
132. Louis CA Reichner JS Henry WL Jr Mastrofrancesco B Gotoh T Mori M Albina JE Distinct arginase isoforms expressed in primary and transformed macrophages: Regulation by oxygen tension Am J Physiol 1998, 274:775-782.
133. Algara-Suarez P Espinosa-Tanguma R 8Br-cGMP mediates relaxation of tracheal smooth muscle through PKA Biochem Biophys Res Commun 2004, 314:597-601. 10.1016/j.bbrc.2003.12.136 14733949
134. Yasuda H Yamaya M Nakayama K Sasaki T Ebihara S Kanda A Asada M Inoue D Suzuki T Okazaki T Takahashi H Yoshida M Kaneta T Ishizawa K Yamanda S Tomita N Yamasaki M Kikuchi A Kubo H Sasaki H Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small-cell lung cancer J Clin Oncol 2006, 24:688-694. 10.1200/JCO.2005.04.0436 16446342
135. Leren P The cardiovascular effects of alpha-receptor blocking agents J Hypertens 1992, 10:S11-4. 10.1097/00004872-199200103-00002
136. Kincaid-Smith P Alpha 1-blockers, their antihypertensive efficacy and effects on lipids and lipoprotein J Hum Hypertens 1989, 3:75-83. 2575178
137. Lowe FC Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms Clin Ther 2004, 26:1701-1713. 10.1016/j.clinthera.2004.11.006 15639685
138. Hu ZW Shi XY Hoffman BB Doxazosin inhibits proliferation and migration of human vascular smooth muscle cells independent of α1-adrenergic receptor antagonism J Cardiovasc Pharmacol 1998, 31:833-839. 10.1097/ 00005344-199806000-00006 9641467
139. Sica DA Alpha1-adrenergic blockers: Current usage considerations J Clin Hypertens (Greenwich) 2005, 7:757-762. 10.1111/j.1524-6175.2005.05300.x 16330901
140. Lepor H Jones K Williford W The mechanism of adverse events associated with terazosin: An analysis of the Veterans Affairs cooperative study J Urol 2000, 163:1134-1137. 10.1016/S0022-5347(05)67709-9 10737482
141. Marshall HJ Beevers DG Alpha-adrenoceptor blocking drugs and female urinary incontinence: Prevalence and reversibility Br J Clin Pharmacol 1996, 42:507-509. 10.1046/j.1365-2125.1996.45217.x 8904625 2042702
142. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group Diuretic versus alpha-blocker as first-step antihypertensive therapy: Final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Hypertension 2003, 42:239-246. 10.1161/ 01.HYP.0000086521.95630.5A 12925554
143. Davis BR Furberg CD Wright JT Jr ALLHAT Collaborative Research Group. ALLHAT: Setting the record straight Ann Intern Med 2004, 141:39-46. 15238369
144. Spiegel D Giese-Davis J Depression and cancer: Mechanisms and disease progression Biol Psychiatry 2003, 54:269-282. 10.1016/ S0006-3223(03)00566-3 12893103
145. Ben-Eliyahu S Shakhar G Page GG Stefanski V Shakhar K Suppression of NK cell activity and of resistance to metastasis by stress: A role for adrenal catecholamines and beta-adrenoceptors Neuroimmunomodulation 2000, 8:154-164. 10.1159/000054276 11124582
146. Arias-Montaño JA Berger VA Soria-Jasso LE Young JM Characterisation of alpha1B-adrenoceptors linked to inositol phosphate formation and calcium mobilisation in human astrocytoma U373 MG cells Naunyn Schmiedebergs Arch Pharmacol 1999, 360:533-539. 10.1007/ s002109900125 10598792
147. Scarparo AC Sumida DH Patrão MT Avellar MC Visconti MA Maria de Lauro Castrucci A Catecholamine effects on human melanoma cells evoked by alpha1-adrenoceptors Arch Dermatol Res 2004, 296:112-119. 10.1007/ s00403-004-0488-x 15278367
148. Sood AK Bhatty R Kamat AA Landen CN Han L Thaker PH Li Y Gershenson DM Lutgendorf S Cole SW Stress hormone-mediated invasion of ovarian cancer cells Clin Cancer Res 2006, 12:369-375. 10.1158/1078-0432.CCR-05-1698 16428474
149. Thaker PH Han LY Kamat AA Arevalo JM Takahashi R Lu C Jennings NB Armaiz-Pena G Bankson JA Ravoori M Merritt WM Lin YG Mangala LS Kim TJ Coleman RL Landen CN Li Y Felix E Sanguino AM Newman RA Lloyd M
150. Su F Ouyang N Zhu P Ouyang N Jia W Gong C Ma X Xu H Song E Psychological stress induces chemoresistance in breast cancer by upregulating mdr1 Biochem Biophys Res Commun 2005, 329:888-897. 10.1016/j.bbrc.2005.02.056 15752739
151. Lutgendorf SK Cole S Costanzo E Bradley S Coffin J Jabbari S Rainwater K Ritchie JM Yang M Sood AK Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines Clin Cancer Res 2003, 9:4514-4521. 14555525
152. Sastry KS Karpova Y Prokopovich S Smith AJ Essau B Gersappe A Carson JP Weber MJ Register TC Chen YQ Penn RB Kulik G Epinephrine protects cancer cells from apoptosis via activation of cAMP-dependent protein kinase and BAD phosphorylation J Biol Chem 2007, 282:14094-14100. 10.1074/ jbc.M611370200 17353197
153. Steinberg SF The molecular basis for distinct beta-adrenergic receptor subtype actions in cardiomyocytes Circ Res 1999, 85:1101-1111. 10571542
154. Barber DL Ganz MB Bongiorno PB Strader CD Mutant constructs of the beta-adrenergic receptor that are uncoupled from adenylyl cyclase retain functional activation of Na-H exchange Mol Pharmacol 1992, 41:1056-1060. 1319545
155. Kyprianou N Benning CM Suppression of human prostate cancer cell growth by alpha 1 adrenoceptor antagonists doxazosin, and terazosin via induction of apoptosis Cancer Res 2000, 60:4550-4555. 10969806
156. Alberti C Apoptosis induction by quinazoline-derived alpha 1-blockers in prostate cancer cells: Biomolecular implications and clinical relevance Eur Rev Med Pharmacol Sci 2007, 11:59-64. 17405349
157. Garrison JB Kyprianou N Doxazosin induces apoptosis of benign and malignant prostate cells via a death receptor-mediated pathway Cancer Res 2006, 66:464-472. 10.1158/0008-5472.CAN-05-2039 16397262 1850148
158. Keledjian K Garrison JB Kyprianou N Doxazosin inhibits human vascular endothelial cell adhesion, migration, and invasion J Cell Biochem 2005, 94:374-388. 10.1002/jcb.20240 15526277
159. Lin SC Chueh SC Hsiao CJ Li TK Chen TH Liao CH Lyu PC Guh JH Prazosin displays anticancer activity against human prostate cancers: Targeting DNA and cell cycle Neoplasia 2007, 9:830-839. 10.1593/neo.07475 17971903 2040210
160. Hui H Fernando MA Heaney AP The alpha1-adrenergic receptor antagonist doxazosin inhibits EGFR and NF-kappaB signalling to induce breast cancer cell apoptosis Eur J Cancer 2008, 44:160-166. 10.1016/j.ejca.2007.10.002 18042375
161. Arce C Segura-Pacheco B Perez-Cardenas E Taja-Chayeb L Candelaria M Dueñnas-Gonzalez A Hydralazine target: From blood vessels to the epigenome J Transl Med 2006, 4:10. 10.1186/1479-5876-4-10 16507100 1413557
162. Magee LA Cham C Waterman EJ Hydralazine for treatment of severe hypertension in pregnancy: Meta-analysis BMJ 2003, 327:955-965. 10.1136/ bmj.327.7421.955 14576246 259162
163. Ellershaw DC Gurney AM Mechanisms of hydralazine induced vasodilation in rabbit aorta and pulmonary artery Br J Pharmacol 2001, 134:621-631. 10.1038/sj.bjp.0704302 11588117 1572994
164. Jacobs M Mechanism of action of hydralazine on vascular smooth muscle Biochem Pharmacol 1984, 33:2915-2919. 10.1016/0006-2952(84)90216-8 6236822
165. Jounela AJ Pasanen M Mattila MJ Acetylator phenotype and the antihypertensive response to hydralazine Acta Med Scand 1975, 197;303-306. 1136859
166. Johnston GD Dose response relationship with antihypertensive drugs Pharmac Ther 1992, 55:53-93. 10.1016/0163-7258(92)90029-Y
167. Cornacchia E Golbus J Maybaum J Strahler J Hanash S Richardson B Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity J Immunol 1988, 140;2197-2000. 3258330
168. Segura-Pacheco B Trejo-Becerril C Perez-Cardenas E Taja-Chayeb L Mariscal I Chavez A Acuña C Salazar AM Lizano M Dueñas-Gonzalez A Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy Clin Cancer Res 2003, 9:1596-1603. 12738711
169. Tang B Jiang J [Study of the CpG methylation status of ER alpha gene in estrogen receptor alpha-negative breast cancer cell lines and the role of hydralazine demethylation] Zhonghua Bing Li Xue Za Zhi 2005, 34:283-287. 16181550
170. Law AY Lai KP Ip CK Wong AS Wagner GF Wong CK Epigenetic and HIF-1 regulation of stanniocalcin-2 expression in human cancer cells Exp Cell Res 2008, 314:1823-18230. 10.1016/j.yexcr.2008.03.001 18394600
171. Song Y Zhang C Hydralazine inhibits human cervical cancer cell growth in vitro in association with APC demethylation and re-expression Cancer Chemother Pharmacol 2008. Jun 3
172. Angeles E Vázquez-Valadez VH Vázquez-Valadez O Velazquez-Sanchez M Ramirez A Martinez L Diaz-Barriga S Romero-Rojas A Cabrera G Lopez-Castañares Duenas-Gonzalez A Computational studies of 1-Hydrazinophtalazine (Hydralazine) as antineoplastic agent. Docking studies on methyltransferase Lett Drug Design Discov 2005, 2:282-286. 10.2174/1570180054038413
173. Deng C Lu Q Zhang Z Rao T Attwood J Yung R Richardson B Hydralazine may induce autoimmunity by inhibiting extracellular signal-regulated kinase pathway signaling Arthritis Rheum 2003, 48:746-756. 10.1002/art.10833 12632429
174. Brueckner B Kuck D Lyko F DNA methyltransferase inhibitors for cancer therapy Cancer J 2007, 13:17-22. 10.1097/PPO.0b013e31803c7245 17464242
175. Duenas-Gonzalez A Candelaria M Perez-Plascencia C Perez-Cardenas E de la Cruz-Hernandez E Herrera LA Valproic acid as epigenetic cancer drug: Preclinical, clinical and transcriptional effects on solid tumors Cancer Treat Rev 2008, 34:206-222. 10.1016/j.ctrv.2007.11.003 18226465
176. Josephson ME Caracta AR Ricciutti MA Lau SH Damato AN Electrophysiologic properties of procainamide in man Am J Cardiol 1974, 33:596-603. 10.1016/ 0002-9149(74)90248-3 4820891
177. Koch-Weser J Clinical application of the pharmacokinetics of procaine amide Cardiovasc Clin 1974, 6:63-75. 4613464
178. Koch-Weser J Klein SW Procainamide dosage schedules, plasma concentrations, and clinical effects JAMA 1971, 215:1454-1460. 10.1001/ jama.215.9.1454 5107621
179. Miller RR Greenblatt DJ The clinical use of procainamide Am J Hosp Pharm 1974, 31:889-891. 4607729
180. Goldman P Ingelfinger JA Therapy with antiarrhythmic drugs N Engl J Med 1978, 298:1193-1194. 651949
181. Ellenbogen KA Wood MA Stambler BS Procainamide: A perspective on its value and danger Heart Dis Stroke 1993, 2:473-476. 8137053
182. McDonald E Marino C Procainamide-induced lupus in the elderly Hosp Pract 1993, 28:95-98.
183. Scheinbart LS Johnson MA Gross LA Edelstein SR Richardson BC Procainamide inhibits DNA methyltransferase in a human T cell line J Rheumatol 1991, 18:530-534. 2066944
184. Lin X Asgari K Putzi MJ Gage WR Yu X Cornblatt BS Kumar A Piantadosi S DeWeese TL De Marzo AM Nelson WG Reversal of GSTP1 CpG island hypermethylation and reactivation of pi-class glutathione S-transferase (GSTP1) expression in human prostate cancer cells by treatment with procainamide Cancer Res 2001, 61:8611-8616. 11751372
185. Lee BH Yegnasubramanian S Lin X Nelson WG Procainamide is a specific inhibitor of DNA methyltransferase 1 J Biol Chem 2005, 280:40749-40756. 10.1074/jbc.M505593200 16230360 1989680
186. Smith RB Everett WG Physiology and pharmacology of local anesthetic agents Int Ophthalmol Clin 1973, 13:35-60. 10.1097/ 00004397-197301320-00005 4202608
187. Finder RL Moore PA Adverse drug reactions to local anesthesia Dent Clin North Am 2002, 46:747-757. 10.1016/S0011-8532(02)00018-6 12436829
188. Verrill PJ Adverse reactions to local anaesthetics and vasoconstrictor drugs Practitioner 1975, 214:380-387. 806908
189. Becker DE Reed KL Essentials of local anesthetic pharmacology Anesth Prog 2006, 53:98-108. 10.2344/0003-3006(2006)53[98:EOLAP]2.0.CO;2 17175824 1693664
190. Villar-Garea A Fraga MF Espada J Esteller M Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells Cancer Res 2003, 63:4984-4989. 12941824
191. Zhou H Xu M Luo G [Effects of procaine on human nasopharyngeal carcinoma cell strain CNE-2Z] Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2007, 21:1118-1121. 18330258
192. Kang SC Lee BM DNA methylation of estrogen receptor alpha gene by phthalates J Toxicol Environ Health A 2005, 68:1995-2003. 10.1080/ 15287390491008913 16326419
193. Castellano S Kuck D Sala M Novellino E Lyko F Sbardella G Constrained analogues of procaine as novel small molecule inhibitors of DNA methyltransferase-1 J Med Chem 2008, 51:2321-2325. 10.1021/jm7015705 18345608
194. Balbi A Sottofattori E Mazzei M Sannita WG Study of bioequivalence of magnesium and sodium valproates J Pharm Biomed Anal 1991, 9:317-321. 10.1016/0731-7085(91)80200-S 1911984
195. DeVane CL Pharmacokinetics, drug interactions, and tolerability of valproate Psychopharmacol Bull 2003, 3:25-42. 14624231
196. Loscher W Basic pharmacology of valproate: A review after 35 years of clinical use for the treatment of epilepsy CNS Drugs 2002, 16:669-669. 10.2165/00023210-200216100-00003 12269861
197. Sztajnkrycer MD Valproic acid toxicity: Overview and management J Toxicol Clin Toxicol 2002, 40:789-801. 10.1081/CLT-120014645 12475192
198. Alsdorf R Wyszynski DF Teratogenicity of sodium valproate Expert Opin Drug Saf 2005, 4:345-353. 10.1517/14740338.4.2.345 15794725
199. Gerstner T Bell N König S Oral valproic acid for epilepsy - long-term experience in therapy and side effects Expert Opin Pharmacother 2008, 9:285-292. 10.1517/14656566.9.2.285 18201150
200. Göttlicher M Minucci S Zhu P Krämer OH Schimpf A Giavara S Sleeman JP Lo Coco F Nervi C Pelicci PG Heinzel T Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells EMBO J 2001, 20:6969-69678. 10.1093/emboj/20.24.6969 11742974 125788
201. Phiel CJ Zhang F Huang EY Guenther MG Lazar MA Klein PS Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen J Biol Chem 2001, 27: 36734-36741. 10.1074/jbc.M101287200 11473107
202. Gurvich N Tsygankova OM Meinkoth JL Klein PS Histone deacetylase is a target of valproic acid-mediated cellular differentiation Cancer Res 2004, 6:1079-1086. 10.1158/0008-5472.CAN-03-0799 14871841
203. Marchion DC Bicaku E Daud AI Sullivan DM Munster PN Valproic acid alters chromatin structure by regulation of chromatin modulation proteins Cancer Res 2005, 65:3815-3822. 10.1158/0008-5472.CAN-04-2478 15867379
204. Blaheta RA Michaelis M Driever PH Evolving anticancer drug valproic acid: Insights into the mechanism and clinical studies Med Res Rev 2005, 2:383-397. 10.1002/med.20027 15637697
205. Göttlicher M Valproic acid: An old drug newly discovered as inhibitor of histone deacetylases Ann Hematol 2004, 83:91-92.
206. Michaelis M Doerr HW Cinatl J Jr Valproic acid as anti-cancer drug Curr Pharm Des 2007, 13:33780-3393. 10.2174/138161207782360519 18045192
207. Eyal S Yagen B Sobol E The activity of antiepileptic drugs as histone deacetylase inhibitors Epilepsia 2004, 45:737-744. 10.1111/ j.0013-9580.2004.00104.x 15230695
208. Beutler AS Li S Nicol R Walsh MJ Carbamazepine is an inhibitor of histone deacetylases Life Sci 2005, 76:3107-3115. 10.1016/ j.lfs.2005.01.003 15850602
209. Yki-Järvinen H Thiazolidinediones N Engl J Med 2004, 351:1106-1118. 10.1056/NEJMra041001 15356308
210. Murphy EJ Davern TJ Shakil AO Shick L Masharani U Chow H Freise C Lee WM Bass NM Troglitazone-induced fulminant hepatic failure: Acute Liver Failure Study Group Dig Dis Sci 2000, 45:549-553. 10.1023/ A:1005405526283 10749332
211. Mudaliar S Henry RR New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers Annu Rev Med 2001, 5:239-257. 10.1146/ annurev.med.52.1.239 11160777
212. Nolan JJ Ludvik B Beerdsen P Joyce M Olefsky J Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone N Engl J Med 1994, 331:1188-1193. 10.1056/ NEJM199411033311803 7935656
213. Chao L Marcus-Samuels B Mason MM Moitra J Vinson C Arioglu E Gavrilova O Reitman ML Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones J Clin Invest 2000, 106:1221-1228. 10.1172/JCI11245 11086023 381440
214. Tack CJ Smits P Demacker PN Stalenhoef AF Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects Diabetes Care 1998, 21:796-799. 10.2337/ diacare.21.5.796 9589243
215. Inzucchi SE Maggs DG Spollett GR Page SL Rife FS Walton V Shulman GI Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus N Engl J Med 1998, 338:867-872. 10.1056/ NEJM199803263381303 9516221
216. Kirk JK Pearce KA Michielutte R Summerson JH Troglitazone or metformin in combination with sulfonylureas for patients with type 2 diabetes J Fam Pract 1999, 48:879-882. 10907625
217. Horton ES Whitehouse F Ghazzi MN Venable TC Whitcomb RW Troglitazone in combination with sulfonylureas restores glycemic control in patients with type 2 diabetes: The Troglitazone Study Group Diabetes Care 1998, 21:1462-1469. 10.2337/diacare.21.9.1462 9727892
218. Stojanovska L Honisett SY Komesaroff PA The anti-atherogenic effects of thiazolidinediones Curr Diabetes Rev 2007, 3:67-74. 10.2174/ 157339907779802058 18220657
219. Martens FM Visseren FL Lemay J de Koning EJ Rabelink TJ Metabolic and additional vascular effects of thiazolidinediones Drugs 2002, 62:1463-1480. 10.2165/00003495-200262100-00004 12093315
220. Lindberg M Astrup A The role of glitazones in management of type 2 diabetes. A dream or a nightmare? Obes Rev 2007, 8:381-384. 10.1111/ j.1467-789X.2007.00399.x 17716295
221. Arnold N McLean M Chipps DR Cheung NW Effectiveness and side effects of thiazolidinediones for type 2 diabetes Med J Aust 2005, 182:494. 15999431
222. Watts NB D'Alessio DA Type 2 diabetes, thiazolidinediones: Bad to the bone? J Clin Endocrinol Metab 2006, 91:3276-3278. 10.1210/jc.2006-1235 16960122
223. Evans RM The steroid and thyroid hormone receptor superfamily Science 1988, 240:889-895. 10.1126/science.3283939 3283939
224. Werman A Hollenberg A Solanes G Bjorbaek C Vidal-Puig AJ Flier JS Ligand-independent activation domain in the N terminus of peroxisome-proliferator-activated receptor g (PPAR-g) - differential activity of PPAR-g-1 and -2 isoforms and influence of insulin J Biol Chem 1997, 27: 20230-20235. 10.1074/jbc.272.32.20230 9242701
225. Moras D Gronemeyer H The nuclear receptor ligand-binding domain - structure and function Curr Opin Cell Bio 1998, 10:384-391. 10.1016/ S0955-0674(98)80015-X
226. Rees WD McNeil CJ Maloney CA The roles of PPARs in the fetal origins of metabolic health and disease PPAR Res 2008, 2008:459030. 2234254 18288289
227. Schoonjans K Staels B Auwerx J The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation Biochim Biophys Acta 1996, 1302:93-109. 8695669
228. Qi C Zhu Y Reddy JK Peroxisome proliferator-activated receptors, coactivators, and downstream targets Cell Biochem Biophys 2000, 3: 187-204. 10.1385/CBB:32:1-3:187 11330046
229. Kopelovich L Fay JR Glazer RI Crowell JA Peroxisome proliferator-activated receptor modulators as potential chemopreventive agents Mol Cancer Ther 2002, 1:357-363. 12489852
230. Theocharis S Margeli A Vielh P Kouraklis G Peroxisome proliferator-activated receptor-gamma ligands as cell-cycle modulators Cancer Treat Rev 2004, 30:545-554. 10.1016/j.ctrv.2004.04.004 15325034
231. Theocharisa S Margeli A Kouraklis G Peroxisome proliferator activated receptor-gamma ligands as potent antineoplastic agents Curr Med Chem Anticancer Agents 2003, 3:239-251. 10.2174/1568011033482431 12769781
232. Fajas L Debril MB Auwerx J Peroxisome proliferator-activated receptor-gamma: From adipogenesis to carcinogenesis J Mol Endocrinol 2001, 27:1-9. 10.1677/jme.0.0270001 11463572
233. Grommes C Landreth GE Heneka MT Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists Lancet Oncol 2004, 5:419-429. 10.1016/S1470-2045(04)01509-8 15231248
234. Giaginis C Margeli A Theocharis S Peroxisome proliferator-activated receptor-gamma ligands as investigational modulators of angiogenesis Expert Opin Investig Drugs 2007, 16:1561-1572. 10.1517/ 13543784.16.10.1561 17922621
235. Panigrahy D Singer S Shen LQ Butterfield CE Freedman DA Chen EJ Moses MA Kilroy S Duensing S Fletcher C Fletcher JA Hlatky L Hahnfeldt P Folkman J Kaipainen A PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis J Clin Invest 2002, 110:923-932. 151148 12370270
236. Bren-Mattison Y Van Putten V Chan D Winn R Geraci MW Nemenoff RA Peroxisome proliferator-activated receptor-gamma (PPAR(gamma)) inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic non-small-cell lung cancer cells (NSCLC) Oncogene 2005, 24:1412-1422. 10.1038/sj.onc.1208333 15608671
237. Burton JD Castillo ME Goldenberg DM Blumenthal RD Peroxisome proliferator-activated receptor-gamma antagonists exhibit potent antiproliferative effects versus many hematopoietic and epithelial cancer cell lines Anticancer Drugs 2007, 18:525-534. 10.1097/ CAD.0b013e3280200414 17414621
238. Takahashi H Fujita K Fujisawa T Yonemitsu K Tomimoto A Ikeda I Yoneda M Masuda T Schaefer K Saubermann LJ Shimamura T Saitoh S Tachibana M Wada K Nakagama H Nakajima A Inhibition of peroxisome proliferator-activated receptor gamma activity in esophageal carcinoma cells results in a drastic decrease of invasive properties Cancer Sci 2006, 97:854-860. 10.1111/j.1349-7006.2006.00250.x 16805824
239. Schaefer KL Takahashi H Morales VM Harris G Barton S Osawa E Nakajima A Saubermann LJ PPARgamma inhibitors reduce tubulin protein levels by a PPARgamma, PPARdelta and proteasome-independent mechanism, resulting in cell cycle arrest, apoptosis and reduced metastasis of colorectal carcinoma cells Int J Cancer 2007, 120:702-713. 10.1002/ijc.22361 17096328
240. Han S Roman J Rosiglitazone suppresses human lung carcinoma cell growth through PPARgamma-dependent and PPARgamma-independent signal pathways Mol Cancer Ther 2006, 5:430-437. 10.1158/1535-7163.MCT-05-0347 16505118
241. Nemenoff RA Peroxisome proliferator-activated receptor-gamma in lung cancer: Defining specific versus "off-target" effectors J Thorac Oncol 2007, 2:989-992. 10.1097/JTO.0b013e318158cf0a 17975488
242. Seargent JM Yates EA Gill JH GW a potent antagonist of PPARgamma, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARgamma agonist rosiglitazone, independently of PPARgamma activation Br J Pharmacol 9662, 143:933-937. 10.1038/ sj.bjp.0705973
243. Lea MA Sura M Desbordes C Inhibition of cell proliferation by potential peroxisome proliferator-activated receptor (PPAR) gamma agonists and antagonists Anticancer Res 2004, 24:2765-2771. 15517883
244. Demetri GD Fletcher CD Mueller E Sarraf P Naujoks R Campbell N Spiegelman BM Singer S Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma Proc Natl Acad Sci USA 1999, 96:3951-3956. 10.1073/pnas.96.7.3951 10097144 22401
245. Debrock G Vanhentenrijk V Sciot R Debiec-Rychter M Oyen R Van Oosterom A A phase II trial with rosiglitazone in liposarcoma patients Br J Cancer 2003, 89:1409-1412. 10.1038/sj.bjc.6601306 14562008
246. Burstein HJ Demetri GD Mueller E Sarraf P Spiegelman BM Winer EP Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: A phase II study Breast Cancer Res Treat 2003, 79:391-397. 10.1023/A:1024038127156 12846423
247. Kulke MH Demetri GD Sharpless NE Ryan DP Shivdasani R Clark JS Spiegelman BM Kim H Mayer RJ Fuchs CS A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer Cancer J 2002, 8:395-399. 10.1097/00130404-200209000-00010 12416897
248. Yee LD Williams N Wen P Young DC Lester J Johnson MV Farrar WB Walker MJ Povoski SP Suster S Eng C Pilot study of rosiglitazone therapy in women with breast cancer: Effects of short-term therapy on tumor tissue and serum markers Clin Cancer Res 2007, 13:246-252. 10.1158/ 1078-0432.CCR-06-1947 17200362
249. Elias AN Lizotte P Enhanced radioiodine uptake in a patient with poorly differentiated papillary thyroid cancer after treatment with rosiglitazone Clin Nucl Med 2006, 31:517-519. 10.1097/ 01.rlu.0000233148.45744.44 16921272
250. Inzucchi SE Maggs DG Spollett GR Page SL Rife FS Walton V Shulman GI Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus N Engl J Med 1998, 338:867-872. 10.1056/ NEJM199803263381303 9516221
251. Inzucchi SE Maggs DG Spollett GR Page SL Rife FS Walton V Shulman GI Mechanism by which metformin reduces glucose production in type 2 diabetes Endocrinology 1996, 137:113-121. 10.1210/en.137.1.113 8536601
252. Radziuk J Zhang Z Wiernperger N Pye S Effects of metformin on lactate uptake and gluconeogenesis in the perfused rat liver Diabetes 1997, 46:1406-1413. 10.2337/diabetes.46.9.1406 9287039
253. Large V Beylot M Modifications of citric acid cycle activity and gluconeogenesis in streptozocin-induced diabetes and effects of metformin Diabetes 1999, 48:1251-1257. 10.2337/diabetes.48.6.1251 10342812
254. Zhou G Myers R Li Y Chen Y Shen X Fenyk-Melody J Wu M Ventre J Doebber T Fujii N Musi N Hirshman MF Goodyear LJ Moller DE Role of AMP-activated protein kinase in the mechanism of metformin action J Clin Invest 2001, 108:1167-1174. 209533 11602624
255. Owen MR Doran E Halestrap AP Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain Biochem J 2000, 348:607-614. 10.1042/ 0264-6021:3480607 10839993 1221104
256. Scheen AJ Clinical pharmacokinetics of metformin Clin Pharmacokinet 1996, 30:359-371. 8743335
257. Tucker GT Casey C Phillips PJ Connor H Ward JD Woods HF Metformin kinetics in healthy subjects and in patients with diabetes mellitus J Clin Pharmac 1981, 12:235-246.
258. Vidon N Chaussade S Noel M Franchisseur C Huchet B Bernier JJ Metformin in the digestive tract Diabetes Res Clin 1988, 4:223-229. 10.1016/ S0168-8227(88)80022-6
259. Desilets AR Dhakal-Karki S Dunican KC Role of Metformin for weight management in patients without typ 2 diabetes Ann Pharmacother 2008. May 13
260. Helvaci MR Kaya H Borazan A Ozer C Seyhanli M Yalcin A Metformin and parameters of physical health Intern Med 2008, 47:697-703. 10.2169/ internalmedicine.47.0787 18421184
261. Campbell IW Howlett HC Worldwide experience of metformin as an effective glucose-lowing agent: A meta-analysis Diabetes Metab Rev 1995, 11:57-62.
262. Wu MS Johnston P Sheu WH Hollenbeck CB Jeng CY Goldfine ID Chen YD Reaven GM Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDDM patients Diabetes Care 1990, 13:1-8. 10.2337/diacare.13.1.1 2404714
263. Abbas M Gannon M The use of metformin as first line treatment in polycystic ovary syndrome Ir Med J 2008, 101:51-53. 18450250
264. Jenne DE Reimann H Nezu J Friedel W Loff S Jeschke R Müller O Back W Zimmer M Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase Nat Genet 1998, 18:38-43. 10.1038/ng0198-38 9425897
265. Evans JM Donnelly LA Emslie-Smith AM Alessi DR Morris AD Metformin and reduced risk of cancer in diabetic patients BMJ 2005, 330:1304-1305. 10.1136/bmj.38415.708634.F7 15849206 558205
266. Bowker SL Majumdar SR Veugelers P Johnson JA Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin Diabetes Care 2006, 29:254-248. 10.2337/ diacare.29.02.06.dc05-1558 16443869
267. Hardie DG Carling D The AMP-activated protein kinase - fuel gauge of the mammalian cell? Eur J Biochem 1997, 246:259-273. 10.1111/ j.1432-1033.1997.00259.x 9208914
268. Kemp BE Stapleton D Campbell DJ Chen ZP Murthy S Walter M Gupta A Adams JJ Katsis F van Denderen B Jennings IG Iseli T Michell BJ Witters LA AMP-activated protein kinase, super metabolic regulator Biochem Soc Trans 2003, 31:162-168. 12546677
269. Ben Sahra I Laurent K Loubat A Giorgetti-Peraldi S Colosetti P Auberger P Tanti JF Le Marchand-Brustel Y Bost F The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level Oncogene 2008, 27:3576-3586. 10.1038/sj.onc.1211024 18212742
270. Motoshima H Goldstein BJ Igata M Araki E AMPK and cell proliferation - AMPK as a therapeutic target for atherosclerosis and cancer J Physiol 2006, 574:63-71. 10.1113/jphysiol.2006.108324 16613876 1817805
271. Yamauchi T Kamon J Minokoshi Y Ito Y Waki H Uchida S Yamashita S Noda M Kita S Ueki K Eto K Akanuma Y Froguel P Foufelle F Ferre P Carling D Kimura S Nagai R Kahn BB Kadowaki T Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase Nat Med 2002, 8:1288-1295. 10.1038/nm788 12368907
272. Ouchi N Kihara S Arita Y Nishida M Matsuyama A Okamoto Y Ishigami M Kuriyama H Kishida K Nishizawa H Hotta K Muraguchi M Ohmoto Y Yamashita S Funahashi T Matsuzawa Y Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell Circulation 2002, 105:2893-2898. 10.1161/ 01.CIR.0000018622.84402.FF 12070119
273. Mantzoros C Petridou E Dessypris N Chavelas C Dalamaga M Alexe DM Papadiamantis Y Markopoulos C Spanos E Chrousos G Trichopoulos D Adiponectin and breast cancer risk J Clin Endocrinol Metab 2004, 89:1102-1107. 10.1210/jc.2003-031804 15001594
274. Dal Maso L Augustin LS Karalis A Talamini R Franceschi S Trichopoulos D Mantzoros CS La Vecchia C Circulating adiponectin and endometrial cancer risk J Clin Endocrinol Metab 2004, 89:1160-1163. 10.1210/jc.2003-031716 15001602
275. Ishikawa M Kitayama J Kazama S Hiramatsu T Hatano K Nagawa H Plasma adiponectin and gastric cancer Clin Cancer Res 2005, 11:466-472. 10.1158/ 1078-0432.CCR-04-1453 15701829
276. Grossmann ME Nkhata KJ Mizuno NK Ray A Cleary MP Effects of adiponectin on breast cancer cell growth and signaling Br J Cancer 2008, 98:370. 10.1038/sj.bjc.6604166 18182989
277. Cong L Gasser J Zhao J Yang B Li F Zhao AZ Human adiponectin inhibits cell growth and induces apoptosis in human endometrial carcinoma cells, HEC-1-A and RL95 2 Endocr Relat Cancer 2007, 14:713-720. 10.1677/ ERC-07-0065 17914101
278. Zakikhani M Dowling R Fantus IG Sonenberg N Pollak M Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells Cancer Res 2006, 66:10269-10273. 10.1158/0008-5472.CAN-06-1500 17062558
279. Dowling RJ Zakikhani M Fantus IG Pollak M Sonenberg N Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells Cancer Res 2007, 67:10804-10812. 10.1158/ 0008-5472.CAN-07-2310 18006825
280. Isakovic A Harhaji L Stevanovic D Markovic Z Sumarac-Dumanovic M Starcevic V Micic D Trajkovic V Dual antiglioma action of metformin: cell cycle arrest and mitochondria-dependent apoptosis Cell Mol Life Sci 2007, 64:1290-1302. 10.1007/s00018-007-7080-4 17447005
281. Gotlieb WH Saumet J Beauchamp MC Gu J Lau S Pollak MN Bruchim I In vitro metformin anti-neoplastic activity in epithelial ovarian cancer Gynecol Oncol 2008. May 19
282. Padwal RS Majumdar SR Drug treatments for obesity: Orlistat, sibutramine and rimonabant Lancet 2007, 369:71-77. 10.1016/S0140-6736(07)60033-6 17208644
283. Smith S The animal fatty acid synthase: One gene, one polypeptide, seven enzymes FASEB J 1994, 8:1248-1259. 8001737
284. Guerciolini R Mode of action of orlistat Int J Obes Relat Metab Disord 1997, 21:12-23.
285. Zhi J Melia AT Guerciolini R Chung J Kinberg J Hauptman JB Patel IH Retrospective population-based analysis of the dose response (fecal fat excretion) relationship of orlistat in normal and obese volunteers Clin Pharmacol Ther 1994, 56:82-85. 8033498
286. Rucker D Padwal R Li SK Curioni C Lau DC Long term pharmacotherapy for obesity and overweight: Updated meta-analysis BMJ 2007, 335:1194-1199. 10.1136/bmj.39385.413113.25 18006966 2128668
287. Filippatos TD Derdemezis CS Gazi IF Nakou ES Mikhailidis DP Elisaf MS Orlistat-associated adverse effects and drug interactions: A critical review Drug Saf 2008, 31:53-65. 18095746
288. Zhi J Moore R Kanitra L The effects of short-term (21-day) Orlistat treatment on the physiologic balance of six selected macrominerals and microminerals in obese adolescents J Am Collegue Nutr 2003, 22:357-362.
289. Kuhajda FP Fatty-acid Synthase and human cancer: New perspectives on its role in tumor biology Nutrition 2000, 16:202-208. 10.1016/ S0899-9007(99)00266-X 10705076
290. Weiss L Fatty-acid biosynthesis in man, a pathway of minor importance. Purification, optimal assay conditions, and organ distribution of fatty-acid synthase Biol Chem Hoppe Seyler 1986, 367:905-912. 3790257
291. Menendez JA Lupu R Oncogenic properties of the endogenous fatty acid metabolism: Molecular pathology of fatty acid synthase in cancer cells Curr Opin Clin Nutr Metab Care 2006, 9:346-357. 16778562
292. Kuhajda FP Fatty acid synthase and cancer: New application of an old pathway Cancer Res 2006, 66:5977-5980. 10.1158/0008-5472.CAN-05-4673 16778164
293. Shah US Dhir R Gollin SM Chandran UR Lewis D Acquafondata M Pflug BR Fatty acid synthase gene overexpression and copy number gain in prostate adenocarcinoma Hum Pathol 2006, 37:401-409. 10.1016/ j.humpath.2005.11.022 16564913
294. Pflug BR Pecher SM Brink AW Nelson JB Foster BA Increased fatty acid synthase expression and activity during progression of prostate cancer in the TRAMP model Prostate 2003, 57:245-254. 10.1002/pros.10297 14518031
295. Pallasch CP Schwamb J Schulz A Debey S Kofler D Schultze JL Hallek M Ultsch A Wendtner CM Targeting lipid metabolism by the lipoprotein lipase inhibitor orlistat results in apoptosis of B-cell chronic lymphocytic leukemia cells Leukemia 2008, 22:585-592. 10.1038/ sj.leu.2405058 18079738
296. Little JL Wheeler FB Fels DR Koumenis C Kridel SJ Inhibition of fatty acid synthase induces endoplasmic reticulum stress in tumor cells Cancer Res 2007, 67:1262-1269. 10.1158/0008-5472.CAN-06-1794 17283163
297. Menendez JA Vellon L Mehmi I Oza BP Ropero S Colomer R Lupu R Inhibition of fatty acid synthase (FAS) supresses HER2/neub(erbB-2) oncogene overexpression in cancer cell Proc Natl Acad Sci USA 2004, 101:10715-10720. 10.1073/pnas.0403390101 15235125 490000
298. Menendez JA Vellon L Lupu R Antitumoral actions of the anti-obesity drug orlistat (Xenical™) in breast cancer cell: Blockade of cell cycle progresion, promotion of apoptotic cell death and PEA3-mediated transcrptional repression of Her2/neu (erb B-2) oncogene Ann Oncol 2005, 16:1253-1267. 10.1093/annonc/mdi239 15870086
299. Evans M Roberts A Davies S Rees A Medical lipid-regulating therapy: current evidence, ongoing trials and future developments Drugs 2004, 64:1181-1196. 10.2165/00003495-200464110-00003 15161326
300. Evans M Roberts A Rees A The future direction of cholesterol-lowering therapy Curr Opin Lipidol 2002, 13:663-669. 10.1097/ 00041433-200212000-00010 12441891
301. Brown MS Goldstein JL Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth J Lipid Res 1980, 21:505-517. 6995544
302. Tobert JA Lovastatin and beyond: The history of the HMG-CoA reductase inhibitors Nat Rev Drug Discov 2003, 2:517-526. 10.1038/nrd1112 12815379
303. Charles-Schoeman C Khanna D Furst DE McMahon M Reddy ST Fogelman AM Paulus HE Park GS Gong T Ansell BJ Effects of high-dose atorvastatin on antiinflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: A pilot study J Rheumatol 2007, 34:1459-1464. 17552046
304. Desager JP Horsmans Y Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors Clin Pharmacokinet 1996, 31:348-371. 9118584
305. Lennernäs H Fager G Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences Clin Pharmacokinet 1997, 32:403-425. 9160173
306. Igel M Sudhop T von Bergmann K Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins) Eur J Clin Pharmacol 2001, 57:357-364. 10.1007/s002280100329 11599653
307. Tomlinson B Chan P Lan W How well tolerated are lipid-lowering drugs? Drugs Aging 2001, 18:665-683. 10.2165/00002512-200118090-00003 11599634
308. Bays H Statin safety: An overview and assessment of the data - 2005 Am J Cardiol 2006, 97:6C-26C. 10.1016/j.amjcard.2005.12.006 16581330
309. Armitage J The safety of statins in clinical practice Lancet 2007, 370:1781-1790. 10.1016/S0140-6736(07)60716-8 17559928
310. Cholesterol Treatment Trialists' (CTT) Collaborators Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins Lancet 2005, 366:1267-1278. 10.1016/S0140-6736(05)67394-1 16214597
311. Cholesterol Treatment Trialists' (CTT) Collaborators Kearney PM Blackwell L Collins R Keech A Simes J Peto R Armitage J Baigent C Cholesterol Treatment Trialists' (CTT). Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: A meta-analysis Lancet 2008, 371:117-125. 10.1016/ S0140-6736(08)60104-X 18191683
312. Executive summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel III) JAMA 2001, 285:2486-2497. 10.1001/jama.285.19.2486 11368702
313. Swanson KM Hohl RJ Anti-cancer therapy: Targeting the mevalonate pathway Curr Cancer Drug Targets 2006, 6:15-37. 10.2174/156800906775471743 16475974
314. Casey PJ Protein lipidation in cell signaling Science 1995, 268:221-225. 10.1126/science.7716512 7716512
315. Rando RR Chemical biology of protein isoprenylation/methylation Biochim Biophys Acta 1996, 1300:5-16. 8608162
316. Seabra MC Mules EH Hume AN Rab GTPases, intracellular traffic and disease Trends Mol Med 2002, 8:23-30. 10.1016/S1471-4914(01)02227-4 11796263
317. Pruitt K Der CJ Ras and Rho regulation of the cell cycle and oncogenesis Cancer Lett 2001, 171:1-10. 10.1016/S0304-3835(01)00528-6 11485822
318. Chan KK Oza AM Siu LL The statins as anticancer agents Clin Cancer Res 2003, 9:10-19. 12538446
319. Notarnicola M Messa C Pricci M Guerra V Altomare DF Montemurro S Caruso MG Up-regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in left-sided human colon cancer Anticancer Res 2004, 24:3837-3842. 15736419
320. Caruso MG Notarnicola M Cavallini A Di Leo A 3-Hydroxy-3-methylglutaryl coenzyme A reductase activity and low-density lipoprotein receptor expression in diffuse-type and intestinal-type human gastric cancer J Gastroenterol 2002, 37:504-508. 10.1007/s005350200078 12162407
321. Banker DE Mayer SJ Li HY Willman CL Appelbaum FR Zager RA Cholesterol synthesis and import contribute to protective cholesterol increments in acute myeloid leukemia cells Blood 2004, 104:1816-1824. 10.1182/ blood-2004-01-0395 15161671
322. Hindler K Cleeland CS Rivera E The role of statins in cancer therapy Oncologist 2006, 11:306-315. 10.1634/theoncologist.11-3-306 16549815
323. Fritz G HMG-CoA reductase inhibitors (statins) as anticancer drugs (review) Int J Oncol 2005, 27:1401-1409. 16211237
324. Katz MS Therapy insight: Potential of statins for cancer chemoprevention and therapy Nat Clin Pract Oncol 2005, 2:82-89. 10.1038/ncponc0097 16264880
325. Sleijfer S Gaast van der A Planting AS Stoter G Verweij J The potential of statins as part of anti-cancer treatment Eur J Cancer 2005, 41:516-522. 10.1016/j.ejca.2004.12.009 15737555
326. Pronk GJ Bos JL The role of p21ras in receptor tyrosine kinase signalling Biochim Biophys Acta 1994, 1198:131-147. 7819271
327. Hall A Rho GTPases and the actin cytoskeleton Science 1998, 279:509-514. 10.1126/science.279.5350.509 9438836
328. Aznar S Lacal JC Rho signals to cell growth and apoptosis Cancer Lett 2001, 165:1-10. 10.1016/S0304-3835(01)00412-8 11248412
329. Adamson P Marshall CJ Hall A Tilbrook PA Post-translational modifications of p21rho proteins J Biol Chem 1992, 267:20033-20038. 1400319
330. Armstrong SA Hannah VC Goldstein JL Brown MS CAAX geranylgeranyl transferase transfers farnesyl as efficiently as geranylgeranyl to RhoB J Biol Chem 1995, 270:7864-7868. 10.1074/jbc.270.43.25879 7713879
331. Wu J Wong WW Khosravi F Minden MD Penn LZ Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis Cancer Res 2004, 64:6461-6468. 10.1158/ 0008-5472.CAN-04-0866 15374955
332. Ogunwobi OO Beales IL Statins inhibit proliferation and induce apoptosis in Barrett's esophageal adenocarcinoma cells Am J Gastroenterol 2008, 103:825-837. 10.1111/j.1572-0241.2007.01773.x 18371146
333. Jiang K Coppola D Crespo NC Nicosia SV Hamilton AD Sebti SM Cheng JQ The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis Mol Cell Biol 2000, 20:139-148. 85069 10594016
334. Du W Liu A Prendergast GC Activation of the PI30K-AKT pathway masks the proapoptotic effects of farnesyltransferase inhibitors Cancer Res 1999, 59:4208-4212. 10485456
335. Hirai A Nakamura S Noguchi Y Yasuda T Kitagawa M Tatsuno I Oeda T Tahara K Terano T Narumiya S Kohn LD Saito Y Geranylgeranylated rho small GTPase(s) are essential for the degradation of p27Kip1 and facilitate the progression from G1 to S phase in growth-stimulated rat FRTL-5 cells J Biol Chem 1997, 272:13-16. 10.1074/jbc.272.1.13 8995216
336. Park WH Lee YY Kim ES Seol JG Jung CW Lee CC Kim BK Lovastatin-induced inhibition of HL-60 cell proliferation via cell cycle arrest and apoptosis Anticancer Res 1999, 19:3133-3140. 10652602
337. Sivaprasad U Abbas T Dutta A Differential efficacy of 3-hydroxy-3-methylglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells Mol Cancer Ther 2006, 5:2310-1316. 10.1158/ 1535-7163.MCT-06-0175 16985065
338. Rao S Porter DC Chen X Herliczek T Lowe M Keyomarsi K Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase Proc Natl Acad Sci USA 1999, 96:7797-7802. 10.1073/pnas.96.14.7797 10393901 22141
339. Ukomadu C Dutta A Inhibition of cdk2 activating phosphorylation by mevastatin J Biol Chem 2003, 278:4840-4846. 10.1074/jbc.M208658200 12475985
340. Cyrus-David MS Weinberg A Thompson T Kadmon D The effect of statins on serum prostate specific antigen levels in a cohort of airline pilots: A preliminary report J Urol 2005, 173:1923-1925. 10.1097/ 01.ju.0000158044.94188.88 15879782
341. Koomen ER Joosse A Herings RM Casparie MK Bergman W Nijsten T Guchelaar HJ Is statin use associated with a reduced incidence, a reduced Breslow thickness or delayed metastasis of melanoma of the skin Eur J Cancer 2007, 43:2580-2589. 10.1016/j.ejca.2007.09.004 17950596
342. Kornblau SM Banker DE Stirewalt D Shen D Lemker E Verstovsek S Estrov Z Faderl S Cortes J Beran M Jackson CE Chen W Estey E Appelbaum FR Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + Ara-C: A phase 1 study Blood 2007, 109:2999-3006. 1852228 17158228
343. Spek van der E Bloem AC Donk van de NW Bogers LH Griend van der R Kramer MH de Weerdt O Wittebol S Lokhorst HM Dose-finding study of high-dose simvastatin combined with standard chemotherapy in patients with relapsed or refractory myeloma or lymphoma Haematologica 2006, 91:542-545. 16585018
344. Holstein SA Knapp HR Clamon GH Murry DJ Hohl RJ Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies Cancer Chemother Pharmacol 2006, 57:155-164. 10.1007/s00280-005-0013-8 16133537
345. Knox JJ Siu LL Chen E Dimitroulakos J Kamel-Reid S Moore MJ Chin S Irish J LaFramboise S Oza AM A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix Eur J Cancer 2005, 41:523-530. 10.1016/j.ejca.2004.12.013 15737556
346. Kawata S Yamasaki E Nagase T Inui Y Ito N Matsuda Y Inada M Tamura S Noda S Imai Y Matsuzawa Y Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial Br J Cancer 2001, 84:886-891. 10.1054/bjoc.2000.1716 11286466
347. Dimitroulakos J Yeger H HMG-CoA reductase mediates the biological effects of retinoic acid on human neuroblastoma cells: Lovastatin specifically targets P-glycoprotein-expressing cells Nat Med 1996, 2:326-333. 10.1038/nm0396-326 8612233
348. Dimitroulakos J Lorimer IA Goss G Strategies to enhance epidermal growth factor inhibition: Targeting the mevalonate pathway Clin Cancer Res 2006, 12:4426-4431. 10.1158/1078-0432.CCR-06-0089
349. Lasek W Giermasz A Kuc K Wañkowicz A Feleszko W Gołab J Zagozdzon R Stokłosa T Jakóbisiak M Potentiation of antitumor effects of tumor necrosis factor alpha and interferon gamma by macrophage-colony-stimulating factor in a MmB16 melanoma model in mice Cancer Immunol Immunother 1995, 40:315-321. 10.1007/BF01519632 7600564
350. Feleszko W Mlynarczuk I Balkowiec-Iskra EZ Czajka A Switaj T Stoklosa T Giermasz A Jakóbisiak M Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice Clin Cancer Res 2000, 6:2044-2052. 10815931
351. Holstein SA Hohl RJ Interaction of cytosine arabinoside and lovastatin in human leukemia cells Leuk Res 2001, 25:651-660. 10.1016/ S0145-2126(00)00162-4 11397469
352. Feleszko W Zagozdzon R Gołab J Jakóbisiak M Potentiated antitumour effects of cisplatin and lovastatin against MmB16 melanoma in mice Eur J Cancer 1998, 34:406-411. 10.1016/S0959-8049(97)10034-X 9640231
353. Holstein SA Hohl RJ Synergistic interaction of lovastatin and paclitaxel in human cancer cells Mol Cancer Ther 2001, 1:141-149. 12467231
354. Schlitzer M Malaria chemotherapeutics part I: History of antimalarial drug development, currently used therapeutics, and drugs in clinical development ChemMedChem 2007, 2:944-986. 10.1002/cmdc.200600240 17530725
355. Canadian rheumatology association Canadian Consensus Conference on hydroxychloroquine J Rheumatol 2000, 27:2919-2921. 11128686
356. Slater AF Chloroquine: Mechanism of drug action and resistance in Plasmodium falciparum Pharmacol Ther 1993, 57:203-235. 10.1016/ 0163-7258(93)90056-J 8361993
357. Cambiaggi A Unusual ocular lesions in a case of systemic lupus erythematosus Arch Ophthalmol 1957, 57:451-453.
358. Hobbs HE Calnan CD The ocular complications of chloroquine therapy Lancet 1958, 1:1207-1209. 10.1016/S0140-6736(58)91911-1 13550971
359. Jeong JY Jue DM Chloroquine inhibits processing of tumor necrosis factor in lipopolysaccharide-stimulated RAW 264.7 macrophages J Immunol 1997, 158:4901-4907. 9144507
360. Bondeson J Sundler R Antimalarial drugs inhibit phospholipase A2 activation and induction of interleukin 1beta and tumor necrosis factor alpha in macrophages: Implications for their mode of action in rheumatoid arthritis Gen Pharmacol 1998, 30:357-366. 10.1016/ S0306-3623(97)00269-3 9510087
361. Borne van den BE Dijkmans BA de Rooij HH le Cessie S Verweij CL Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells J Rheumatol 1997, 24:55-60. 9002011
362. Savarino A Lucia MB Giordano F Cauda R Risks and benefits of chloroquine use in anticancer strategies Lancet Oncol 2006, 7:792-793. 10.1016/ S1470-2045(06)70875-0 17012039
363. Savarino A Boelaert JR Cassone A Majori G Cauda R Effects of chloroquine on viral infections: An old drug against today's diseases Lancet Infect Dis 2003, 3:722-727. 10.1016/S1473-3099(03)00806-5 14592603
364. Carew JS Nawrocki ST Cleveland JL Modulating autophagy for therapeutic benefit Autophagy 2007, 3:464-467. 17495516
365. Amaravadi RK Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma J Clin Invest 2007, 117:326-336. 10.1172/ JCI28833 17235397 1765515
366. Zaidi AU Chloroquine-induced neuronal cell death is p53 and Bcl-2 family-dependent but caspase-independent J Neuropathol Exp Neurol 2001, 60:937-945. 11589424
367. Carew JS Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance Blood 2007, 110:313-322. 10.1182/blood-2006-10-050260 17363733 1896119
368. Boya P Inhibition of macroautophagy triggers apoptosis Mol Cell Biol 2005, 25:1025-1040. 10.1128/MCB.25.3.1025-1040.2005 15657430 543994
369. Paludan C Endogenous MHC class II processing of a viral nuclear antigen after autophagy Science 2005, 307:593-596. 10.1126/science.1104904 15591165
370. Shacka JJ Bafilomycin A1 inhibits chloroquine-induced death of cerebellar granule neurons Mol Pharmacol 2006, 69:1125-1136. 10.1124/ mol.105.018408 16391239
371. Maclean KH Dorsey FC Cleveland JL Kastan MB Targeting lysosomal degradation induces p53-dependent cell death and prevents cancer in mouse models of lymphomagenesis J Clin Invest 2008, 118:79-88. 10.1172/ JCI33700 18097482 2148253
372. Sotelo J Briceño E López-González MA Adding chloroquine to conventional treatment for glioblastoma multiforme: A randomized, double-blind, placebo-controlled trial Ann Intern Med 2006, 144:337-343. 16520474
373. Spitz IM Bardin CW Mifepristone (RU486), a modulator of progestin and glucocorticoid action N Engl J Med 1993, 329:404-412. 10.1056/ NEJM199308053290607 8326975
374. Christian-Maitre S Bouchard P Spitz IM Drug Therapy: Medical termination of pregnancy N Engl J Med 2000, 342:946-956. 10.1056/NEJM200003303421307 10738054
375. Kekkonen R Heikinheimo O Mandelin E Lähteenmäki P Pharmacokinetics of mifepristone after low oral doses Contraception 1996, 54:229-234. 10.1016/S0010-7824(96)00193-X 8922876
376. Brogden RN Goa KL Faulds D Mifepristone. A review of its pharmacodynamic and pharmacokinetics properties, and therapeutics potential Drugs 1993, 45:384-409. 7682909
377. Attardi BJ Burgenson J Hild SA Reel JR In vitro antiprogestational/ antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and syntetic derivatives of CDB-2914, CDB-4124, and mifepristone J Steroid Biochem Mol Biol 2004, 88:277-288. 10.1016/j.jsbmb.2003.12.004 15120421
378. Sitruk-Ware R Spitz IM Pharmacological properties of mifepristone: toxicology and safety in animal and human studies Contraception 2003, 68:409-420. 10.1016/S0010-7824(03)00171-9 14698070
379. Liang Y Hou M Kallab AM Barrett JT El Etreby F Schoenlein PV Induction of antiproliferation and apoptosis in estrogen receptor negative MDA-231 human breast cancer cells by mifepristone and 4-hydroxytamoxifen combination therapy: A role for TGFbeta1 Int J Oncol 2003, 23:369-380. 12851686
380. El Etreby MF Liang Y Wrenn RW Schoenlein PV Additive effect of mifepristone and tamoxifen on apoptotic pathways in MCF-7 human breast cancer cells Breast Cancer Res Treat 1998, 51:149-168. 10.1023/ A:1006078032287 9879777
381. Rose FV Barnea ER Response of human ovarian carcinoma cell lines to antiprogestin mifepristone Oncogene 1996, 12:999-1003. 8649817
382. Rocereto TF Saul HM Aikins JA Jr Paulson J Phase II study of mifepristone (RU486) in refractory ovarian cancer Gynecol Oncol 2000, 77:429-432. 10.1006/gyno.2000.5789 10831354
383. Goyeneche AA Carón RW Telleria CM Mifepristone inhibits ovarian cancer cell growth in vitro and in vivo Clin Cancer Res 2007, 13:3370-3379. 10.1158/1078-0432.CCR-07-0164 17545545 2505183
384. Schneider CC Gibb RK Taylor DD Wan T Gerçel-Taylor C Inhibition of endometrial cancer cell lines by mifepristone (RU 486) J Soc Gynecol Investig 1998, 5:334-338. 10.1016/S1071-5576(98)00037-9 9824816
385. El Etreby MF Liang Y Johnson MH Lewis RW Antitumor activity of mifepristone in the human LNCaP, LNCaP-C4, and LNCaP-C4-2 prostate cancer models in nude mice Prostate 2000, 42:99-106. 10.1002/ (SICI)1097-0045(20000201)42:2<99::AID-PROS3>3.0.CO;2-I 10617866
386. Li DQ Wang ZB Bai J Zhao J Wang Y Hu K Du YH Effects of mifepristone on proliferation of human gastric adenocarcinoma cell line SGC-7901 in vitro World J Gastroenterol 2004, 10:2628-2631. 15309708
387. Gaddy VT Barrett JT Delk JN Kallab AM Porter AG Schoenlein PV Mifepristone induces growth arrest, caspase activation, and apoptosis of estrogen receptor-expressing, antiestroogen-resistant breast cancer cell Clin Cancer Res 2004, 10:5215-5225. 10.1158/1078-0432.CCR-03-0637 15297425
388. Kaufmann SH Earnshaw WC Induction of apoptosis by cancer chemotherapy Exp Cell Res 2000, 256:42-49. 10.1006/excr.2000.4838 10739650
389. Murphy AA Zhou MH Malkapuram S Santanam N Parthasarathy S Sidell N RU486-induced growth inhibition of human endometrial cells Fertil Steril 2000, 74:1014-1019. 10.1016/S0015-0282(00)01606-X 11056251
390. Hand S Sidell N RU486-induced growth inhibition of human endometrial cells involves the nuclear factor-kappa B signaling pathway J Clin Endocrinol Metab 2003, 88:713-719. 10.1210/jc.2002-020876 12574204
391. Payen L Delugin L Courtois A Trinquart Y Guillouzo A Fardel O Reversal of MRP-mediated multidrug resistance in human lung cancer cells by the antiprogestatin drug RU486 Biochem Biophys Res Commun 1999, 258:513-518. 10.1006/bbrc.1999.0671 10329417
392. Li DQ Wang ZB Bai J Zhao J Wang Y Hu K Du YH Effects of mifepristone on proliferation of human gastric adenocarcinoma cell line SGC-7901 in vitro World J Gastroenterol 2004, 10:2628-2631. 15309708
393. Yang CP DePinho SG Greenberger LM Arceci RJ Horwitz SB Progesterone interacts with P-glycoprotein in multidrug-resistant cells and in the endometrium of gravid uterus J Biol Chem 1989, 264:782-788. 2562956
394. Ueda K Okamura N Hirai M Tanigawara Y Saeki T Kioka N Komano T Hori R Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone J Biol Chem 1992, 267:24248-24252. 1360010
395. Hait WN Aftab DT Rational design and pre-clinical pharmacology of drugs for reversing multidrug resistance Biochem Pharmacol 1992, 43:103-107. 10.1016/0006-2952(92)90667-8 1346493
396. Lecureur V Fardel O Guillouzo A The antiprogestatin drug RU 486 potentiates doxorubicin cytotoxicity in multidrug resistant cells through inhibition of P-glycoprotein function FEBS Lett 1994, 355:187-191. 10.1016/0014-5793(94)01186-9 7982498
397. Wang G Shang HL Xie Y Xiao P Li XJ Lin TC Li GY Effects of mifepristone on the proliferation, apoptosis and cis-diamminedichloroplatinum sensitivity of cultured chemoresistant human ovarian cancer cells Chin Med J (Engl) 2005, 20:333-336.
398. Liu Y Wang LL Deng Y Enhancement of antitumor effect of cisplatin against human ovarian carcinoma cells by mifepristone in vivo Di Yi Jun Yi Da Xue Xue Bao 2003, 23:242-244. 12651241
399. Garcia-Lopez P Jurado R Antihormonal Agents in the Citotoxicity Increase of Anticancer Drugs in Cervical Cancer In. Trends in cervical cancer research. Editor: Héctor T. Varaj. Editorial: Nova Science Publishers Inc Hauppauge NY 2007:61-88. ISBN 1-60021-299-9
400. Sartor O Figg WD Mifepristone: Antineoplastic studies Clin Obstet Gynecol 1996, 39:498-505. 10.1097/00003081-199606000-00023 8734014
401. Matsuda Y Kawamoto K Kiya K Kurisu K Sugiyama K Uozumi T Antitumor effects of antiprogesterones on human meningioma cells in vitro and in vivo J Neurosurg 1994, 80:527-534. 8113866
402. Lamberts SW Tanghe HL Avezaat CJ de Jong H Mifepristone (RU 486) treatment of meningiomas J Neurol Neurosurg Psychiatry 1992, 55:486-490. 1014906 1619417 10.1136/jnnp.55.6.486
403. Grunberg SM Weiss MH Russell CA Spitz IM Ahmadi J Sadun A Sitruk-Ware R Long-term administration of mifepristone (RU486): Clinical tolerance during extended treatment of meningioma Cancer Invest 2006, 24:727-733. 10.1080/07357900601062339 17162554
404. Koivisto-Korander R Leminen A Heikinheimo O Mifepristone as treatment of recurrent progesterone receptor-positive uterine leiomyosarcoma Obstet Gynecol 2007, 109:512-514. 17267877
405. Druker BJ Imatinib: Paradigm or anomaly? Cell Cycle 2004, 3:833-835. 15254412
406. Csermely P Agoston V Pongor S The efficiency of multi-target drugs: The network approach might help drug design Trends Pharmacol Sci 2005, 26:178-182. 10.1016/j.tips.2005.02.007 15808341
407. Frantz S Drug discovery: Playing dirty Nature 2005, 437:942-943. 10.1038/ 437942a 16222266
408. Mencher SK Wang LG Promiscuous drugs compared to selective drugs (promiscuity can be a virtue) BMC Clin Pharmacol 2005, 5:3. 10.1186/ 1472-6904-5-3 15854222 1090568
409. Zhang X Crespo A Fernández A Turning promiscuous kinase inhibitors into safer drugs Trends Biotechnol 2008, 26:295-301. 10.1016/ j.tibtech.2008.02.008 18403035
410. Nielsch U Schäfer S Wild H One target-multiple indications: A call for an integrated common mechanisms strategy Drug Discov Today 2007, 12:1025-1031. 10.1016/j.drudis.2007.10.004 18061881
411. Radisky DC Kenny PA Bissell MJ Fibrosis and cancer: Do myofibroblasts come also from epithelial cells via EMT J Cell Biochem 2007, 101:830-839. 10.1002/jcb.21186 17211838
412. Hung RW Chow AW Dissecting the "end game": Clinical relevance, molecular mechanisms and laboratory assessment of apoptosis Clin Invest Med 2004, 27:324-344. 15675113
413. Agoston V Csermely P Pongor S Multiple, weak hits confuse complex systems: A transcriptional regulatory network as an example Phys Rev E 2005, 71:051909. 10.1103/PhysRevE.71.051909
414. Shoshan MC Linder S Target specificity and off-target effects as determinants of cancer drug efficacy Expert Opin Drug Metab Toxicol 2008, 4:273-280. 10.1517/17425255.4.3.273 18363542
415. Shishehbor MH Amini R Raymond RE Bavry AA Brener SJ Kapadia SR Whitlow PL Ellis SG Bhatt DL Safety and efficacy of overlapping sirolimus-eluting versus paclitaxel-eluting stents Am Heart J 2008, 155:1075-1080. 10.1016/j.ahj.2008.01.017 18513522
416. Andreoli CM Miller JW Anti-vascular endothelial growth factor therapy for ocular neovascular disease Curr Opin Ophthalmol 2007, 18:502-508. 10.1097/ICU.0b013e3282f0ca54 18163003
417. Roger S Potier M Vandier C Besson P Le Guennec JY Voltage-gated sodium channels: New targets in cancer therapy Curr Pharm Des 2006, 12:3681-3695. 10.2174/138161206778522047 17073667
418. Fishman MC Porter JA Pharmaceuticals: A new grammar for drug discovery Nature 2005, 437:491-493. 10.1038/437491a 16177777